Project Assistant
Resume:
Name: John Randall Slemmon
Biomarker Strategy / Translational Pharmacology: Measurement Development for Drug Discovery
and Clinical Trials, including Efficacy, Safety, and Mechanism of Action. Experience in
Neurodegeneration, Inflammation, Psychotherapeutics, Metabolics and Biomarker
Characterization.
Address:
Home: 5 Emerald Ct.
West Windsor, NJ 08550
Office: Bristol-Myers Squibb Company
311 Pennington-Rocky Hill Road (3b-0.03)
Pennington, NJ 08534
Phone:
Office: 609-***-****
Cell: 609-***-****
Home: 609-***-****
E-mail: *****.*******@***.***
Professional Experience
2006- Associate Director, Bristol-Myers Squibb Company, Lead - Neuroscience Biomarker Group,
Discovery Medicine and Clinical Pharmacology
2001-2005 Research Fellow (Assoc. Dir.), Pfizer Pharm. Co., Div. of Biology, Dept. of Discovery
Biomarkers, Ann Arbor, MI (formerly Pharmacia Corp., Skokie IL)
1997-01 Assistant Director, GlaxoSmithKline R&D, Dept. of Protein Biochemistry, King of Prussia,
PA (formerly SmithKline Beecham)
1992-97 Associate Professor of Biochemistry and Biophysics and Associate Professor of
Neurobiology and Anatomy, University of Rochester, School of Medicine and Dentistry,
Rochester, NY
1986-92 Assistant Professor of Biochemistry and Assistant Professor of Neurobiology and Anatomy,
University of Rochester, School of Medicine and Dentistry, Rochester, NY
1985-86 Visiting Scientist, Beckman Research Institute of the City of Hope, Duarte, CA
1982-85 Postdoctoral Fellow - Roche Institute of Molecular Biology, Roche Research Center,
Hoffmann-LaRoche Pharmaceuticals, Nutley, NJ
1976-81 Biochemistry Predoctoral Trainee, University of Southern California, Los Angeles, CA
Education
School or College Field of Study Degree Earned Year
J. Randall Slemmon
Univ. of Calif., San Diego Biology B.A. 1974
Univ. of Southern Calif. Biochemistry Ph.D. 1981
Experience
2006- Leader: Clinical Biomarker Working Group in Neurosciences. Coordinating biomarker
activities from lead candidate nomination through Phase 3. Primary focus is Alzheimer’s
disease and FTD neurodegeneration, with an additional effort on psychiatric disorders.
Integrating biomarker strategies that include genetic, immunochemical, imaging (primarily
MRI and AV45-PET), and new technology approaches. Back-translated candidate clinical
measurements to discovery biology for validation of MOA in animal models prior to Ph 1
studies. Have provided new PD biomarker measures to neuroscience, cardiovascular and
cancer therapeutic areas. Used cytometric flow assays to monitor T, B, NK cell
proliferation, T Naive (CD4 and CD8) cells, and B Naive/Non-switched memory cells in
whole blood.
Provided new assays that overcame the problem of false-positive Abeta peptide
measurements (HPLC-based). New data drove the fast track status of the GSI compound and
has improved the accuracy of the Abeta 1-42 cutoff for identifying prodromal AD subjects.
Developed new strategies and techniques for measuring transient changes in HPA axis for
use as PD markers in psychotherapeutic projects. Experience exploiting the need to develop
protein/protein fragment-based biomarker strategies for neurodegeneration (Abeta, Tau,
PGRN, etc.). Currently supporting PD biomarkers for 5 early-phase clinical trials and 2 full
development programs.
2003-05 Developed new plasma-based assays to measure degradation products of aggrecan and
collagen II for OA clinical proof-of-concept study. Formed team to develop assays for
evaluating Telmisartan action in glucose utilization and dyslipidemia projects. Developed
assays based on neurogenesis for studying new targets for depression. Deployed and
characterized Multiplex Immunoassays for measures of inflammation and oxidative stress.
2001-03 Biomarker assay development for target and mechanism Biomarkers. Worked with more
than 26 pharmacology teams covering Inflammation, Psychotherapeutics,
Cardiovascular/Atherosclerosis, Dyslipidemia, Dermatology, Cancer and Neurodegenerative
diseases. Developed improved techniques for measuring blood-borne protein fragments and
other analytes for Inflammation, Cardiovascular and other clinical studies. Developed
multiplex assay strategies to support clinical and preclinical studies in Cardiovascular
Disease and Psychotherapeutic Disorders. Member of Pharmacogenomics Global Team.
Participant on teams charged with sample collection for early clinical feasibility studies.
2001-03 BACE and GSI projects (Alzheimer’s Disease). Developed plasma/whole blood based
assays for total Abeta peptides that can recover Abeta from complexes and display multiple
MW forms in one process. HPLC-Linked ELISA. Supported Phase 1 Biomarker project for
inhibitors of Beta Secretase and Gamma Secretase. Identified peptide fragments from
cardiac muscle whose production was blocked by inhibitors to MMP13.
2
J. Randall Slemmon
1979-92 Neurotransmitter Synthetic Enzymes (purification, characterization, genetics, processing,
immunocytochemistry). Peptide biochemistry, Cerebellin discovery. Immunocytochemistry,
Protein Characterization and Antibody-Based Assays.
1990-96 Neurodegenerative Disease Mechanisms (Alzheimer’s Disease, Huntington’s Disease),
Peptide Proteomics. Researched biomarkers of Alzheimer’s Disease. Participated in Clinical
Neurology Core for neurodegenerative diseases.
1994-01 Calcium-Mediated Cell Signaling and Cell Death. CNS and Cardiovascular Disease.
Developed assay strategies for blood borne measures of cardiac insult during hypertrophy.
Regulation of Calmodulin, nNOS and CamKII. Whole cell assay development.
1997-01 Orphan GPCR studies. Screened over 150 Orphan GPCR receptors (FLIPR, cAMP, other
whole cell assays) against know ligands and tissue extracts. Led bioactive peptide group that
was first to identify a new bioactive ligand, Prokineticin (BV8) to orphan receptor GPR73.
1997- Recombinant protein purification and characterization from bacterial and eukaryotic
systems. Bioactive proteins/peptides.
Supervisory Experience
2006- Supervised a group of 4 engaged in developing techniques and assessing measurements to
support safety and PD assays in clinical trials. In collaboration with discovery, carry out
assays on preclinical animal models as part of a translational strategy. Work with scientists
developing imaging and qEEG measures in order to align molecular measurements with
physiological endpoints.
2003-05 Supervised 3 groups with a total of 22 scientists engaged in Bioinformatics, RNA
measurements (Affymetrix and traditional) and Protein-based assay construction. Focus was
on enabling biomarker strategies and developing new assay strategies that could bridge
animal models with clinical measures.
2001-03 Began building new biomarker group at Pharmacia Corp., principally for OA and
Neuroscience therapeutic areas. Pfizer merger happened shortly thereafter.
1997-01 Supervised several types of laboratory teams (cell biology, protein analysis, FLIPR assay
development). Efforts included protein reagent preparation, GPCR ligand fishing and
calcium signaling studies.
1986-97 Trained Postdoctoral, Medical, Undergraduate and Graduate scientists in a lab supported by
my NSF and NIH-funded grants. This included support from departmental NIH training
grants.
External Activities
2007- Member, Foundation for the NIH, Neuroscience Biomarker Steering Committee
1990- Editorial Advisory Board, Neurobiology of Aging
3
J. Randall Slemmon
1992- External Grants Referee, Alzheimer’s Association, Chicago, IL.
2004- Reviewer, J. Chrom. B.
2002- Reviewer, Molecular Brain Research
2001 Member, Special Study Section ZRG1 (Proteomics), Bacteriology & Mycology (BM-2),
CSR, NIH
2000 Member, Special Study Section SSS K (03) (Proteomics), CSR, NIH
1999 Consultant to the Functional Genomics Workshop (Proteomics), National Eye Institute
(NIH), Bethesda, MD, September 14-15.
1999 Member, SPE Study Section ZNS1-SRB-P(01), NINDS (NIH), New Technologies to
Analyze Gene Expression in the Nervous System (Proteomics).
1995-01 Specialist Referee, Hong Kong Research Grants Council
1996-97 Visiting Professor, RWJ Pharmaceutical Research Institute, Drug Discovery, Johnson and
Johnson, Springhouse, PA
1994-97 Internal Advisory Board, Alzheimer’s Research Center, Univ. of Rochester
Pfizer Activities
AA Representative to Biology Intellectual Property team
Member, Pharmacogenomics (Polyomics) Working Group
Member, AA Translational Pharmacology Team
Member, AA Technology Biomarker Team
Member, AA CNS-Early Pipeline Team
Previous GlaxoSmithKline (SKB) Activities
Protein Purification/Characterization Manager/Supervisor
Peptide Biochemistry Team for Ligand Fishing Leader
Calcium-Signaling in Cardiovascular Disease and Cell Death Team Co-leader
Technology Development for Protein/Peptide Biochemistry Organizer
Proteomics Using Chromatographic Platforms Organizer
Past University Activities
4
J. Randall Slemmon
1990-97 Preceptor; NIH Training Grant T32 GM07102, Interdepartmental Training Grant in
Genetics and Regulation
1994-97 Member, Radiation Safety Advisory Committee
1994-97 Member, Alzheimer's Disease Center, Internal Advisory Committee
1989-97 Preceptor; NIA Training Grant 5-T32 AG00107, Training in Geriatrics and Neurobiology
of Aging
1987-90 Departmental Representative to Medical Faculty Council
1986-92 Supervisor, Protein Sequencing and Amino Acid Analysis Core Facility
P ast Principal Academic Research Support and Projects
NIH Title: Biochemistry of Endogenous Neuronal Calmodulin Regulators
Principle Investigator: J. Randall Slemmon
Grant Number: 1 R01 NS33299
Project Period: 8-01-94 to 7-31-99
NIH Title: Leadership and Excellence in Alzheimer's Disease Award
Program Director: Paul D. Coleman
Grant Number: 5 R35 AG09016
Project 4: Differential Peptide Expression in Alzheimer's Disease
Project Leader: J. Randall Slemmon
Project Period: 5/1/90 to 4/30/97.
NSF Title: Processing of Choline Acetyltransferase
Principle Investigator: J. Randall Slemmon
Grant Number: BNS-9021042
Project Period: 4/1/91 to 3/31/94
NSF Title: Processing of Choline Acetyltransferase
Principle Investigator: J. Randall Slemmon
Grant Number: BNS-8715047
Project Period 4/1/88 to 3/31/91
Publications
1. Barber, R.P., Vaughn, J.E., Slemmon, J.R., Salvaterra, P.M., Roberts, E., and Leeman, S.
E. (1979)The origin, distribution and synaptic relationships of substance P axons in rat
spinal cord. J. Comp. Neurol. 184:331-352.
2. Slemmon, J.R., Salvaterra, P.M., and Saito, K. (1980) Preparation and characterization of
peroxidase: anti peroxidase-fab complex. J. Histochem. Cytochem. 28:10-15.
3. Slemmon, J.R., Salvaterra, P.M., Crawford, G.D., and Roberts, E. (1982) Purification of
choline acetyltransferase from Drosophila melanogaster. J. Biol. Chem. 257:3847-3852.
5
J. Randall Slemmon
4. Crawford, G.D., Slemmon, J.R., and Salvaterra, P.M. (1982) Monoclonal antibodies
selective for Drosophila melanogaster choline acetyltransferase. J. Biol. Chem. 257:3853-
3856.
5. Slemmon, J.R., Salvaterra, P.M., and Roberts, E. (1984) Molecular characterization of
choline acetyltransferase from Drosophila melanogaster. Neurochem. Int. 6:519-525.
6. Slemmon, J.R., Blacher, R., Danho, W., Hempstead, J.L., and Morgan, J.I. (1984) Isolation
and sequencing of two cerebellum-specific peptides. Proc. Natl. Acad. Sci. USA 81:6866-
6870.
7. Slemmon, J.R., Danho, W., Hempstead, J.L, and Morgan, J.I. (1985) Cerebellin: A
quantifiable marker for Purkinje cell maturation. Proc. Natl. Sci. USA 82:7145-7148.
8. Itoh, N., Slemmon, J.R., Crawford, G.D., Morita, M., Itakura, K., Hawke, D., Shively, J.E.,
Roberts, E., Williamson, R., and Salvaterra, P.M. (1986) Cloning of Drosophila choline
acetyltransferase cDNA. Proc. Natl. Acad. Sci. USA 83:4081-4085.
9. Morgan, J.I., Slemmon, J.R., Danho, W., Hempstead, J., Berrebi, A.S., and Mugnaini, E.
(1986) Cerebellin and related postsynaptic peptides in the brain of normal and
neurodevelopmentally mutant vertebrates. Synapse 2:117-124.
10. Muñoz-Maines, V.J., Slemmon, J.R., Panicker, M.M., Neighbor, H., and Salvaterra, P.M.
(1987) Production of polyclonal antisera to choline acetyltransferase using a fusion protein
produced by a cDNA clone. J. Neurochem. 50:167-175.
11. Slemmon, J.R., Goldowitz,D., Blacher, R., and Morgan, J.I. (1988) Evidence for the
transneuronal regulation of cerebellin biosynthesis in developing Purkinje pells. J.
Neuroscience 12:4603-4611.
12. Slemmon, J.R. (1989) Sequence analysis of a proteolyzed site in Drosophila choline
acetyltransferase. J. Neurochem. 52:1898-1904.
13. Slemmon, J.R., Campbell, G.A., Selski, D.J. and Bramson, H.N. (1991) The amino terminus
of the putative Drosophila choline acetyltransferase precursor is cleaved to yield the 67
kDa-enzyme. Mol. Brain Rsch. 9:245-252.
14. Avissar, N., Slemmon, J.R., Palmer, I.S. and Cohen, H.J. (1991) Partial sequence of human
plasma glutathione peroxidase and immunologic identification of milk glutathione
peroxidase as the plasma enzyme. J. Nutrition 121:1243-1249.
15. Slemmon, J.R., and Flood, D.G. (1992) Profiling of endogenous brain peptides and small
proteins: Methodology, computer-assisted analysis and application to aging and lesion
models. Neurobiology of Aging 13: 649-660.
16. Wengenack, T.M., Slemmon, J.R. and Coleman, P.D. (1992) Effects of transient forebrain
ischemia on high molecular weight fraction peptides in the rat hippocampus. Molecular
Biology of Aging. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory pp. 23
17. Coleman, P.D., Flood, D.G., O'Banion, M.K., Slemmon, J.R., Wengenack, T., and
Martzen, M.R. (1993) Responses of surviving cells to the death of their neighbor neurons.
In: Alzheimer’s Disease: Advances in Clinical and Basic Research, B. Corain, K. Iqbal,
M. Nicolini, B. Winblad, H. Wisniewski and P. Zatta, eds. John Wiley, Chicester, England,
pp. 183-188.
6
J. Randall Slemmon
18. Slemmon, J.R., Hughes, C.M., Campbell, G.A. and Flood, D.G. (1994) Increased levels of
hemoglobin-derived and other peptides in Alzheimer's disease cerebellum. J. Neurosci. 14,
2225-2235.
19. Slemmon, J.R. and Martzen, M.R. (1994) Neuromodulin (GAP-43) can regulate a
calmodulin-dependent target in vitro. Biochemistry 33, 5653-5660.
20. Wengenack, T.M., Slemmon, J.R., Ordy, J.M., Dunlap, W.P., and Coleman, P.D. (1994)
Vascular and cellular protein changes precede hippocampal pyramidal cell loss following
global ischemia in the rat. Advances in Experimental Medicine and Biology 366, 436-438.
21. Martzen, M. R. and Slemmon, J.R. (1995) The dendritic peptide Neurogranin can regulate a
calmodulin-dependent target. J. Neurochem 64, 92-100.
22. Slemmon, J.R., Morgan, J.I., Fullerton, S.M., Danhoe, W., Hillbush, B. and Wengenack,
T.M. (1996) Camstatins, peptide antagonists of calmodulin based upon a conserved
structural motif in PEP-19, neurogranin and neuromodulin. J. Biol. Chem. 271, 15911-
15917.
23. Slemmon, J.R., Wengenack, T.M. and Flood, D.G. (1997) Peptide profiling as a tool for
studying development and neurological disease. Biopoly 43, 157-170.
24. Wengenack, T. M., Slemmon, J.R. and Ordy, J.M. (1998) Quantitative analysis of peptide
and protein changes in ischemic hippocampal tissue by HPLC. In: Methods in Molecular
Biology: Free Radicals and Antioxidant Protocols. Vol. 108 (Armstrong, D.M., ed.)
Humana Press, Totowa, NJ, pp. 165-180
25. Smith, M.L., Johanson, R.A., Rogers, K.E., Coleman, P.D. and Slemmon, J.R. (1998)
CAP-19, purification and cloning of a neuronal calmodulin-associated protein containing an
IQ motif. Mol. Brain Research 62, 12-24.
26. Wilson, S., Slemmon, J. R., Culp, J.S., Hellmig, B.D., McNulty, D.E., Ames, R.S., Sarau,
H.M., Foley, J.J., Park, J.E., Chambers, J.K., Muir, A.I., Stadel, J.M. and Bergsma, D.
J. (1999) Screening orphan receptors for native ligands. In: G Protein-Coupled Receptors
(Hage, T. and Berstein, G., eds.) CRC Press, New York. pp.97-114.
27. Johanson, R.A., Sarau, H.M., Foley, J.J. and Slemmon, J.R. (2000) Calmodulin-binding
peptide, PEP-19, modulates activation of calmodulin kinase II in situ. J. Neurosci. 20, 2860-
2866.
28. Erhardt, J.A., Legos, J.J., Johanson, R.A., Slemmon, J.R. and Wang, X. (2000) Expression
of PEP-19 inhibits apoptosis of PC12 cells. NeuroReport 11(17), 3719-3723.
29. Slemmon, J.R., Feng B. and Erhardt, J.A. (2000) Small proteins that modulate calmodulin-
dependent signal transduction: Effects of PEP-19, neuromodulin and neurogranin on
enzyme activation and cellular homeostasis. Molecular Neurobiology 22, 99-113.
30. Feng, B., Patel, A.H., Keler, P.M. and Slemmon, J.R. (2001) Fast characterization of intact
proteins using a high-throughput eight-channel parallel LC/MS system. Rapid Comm. Mass
Spectrometry 15, 821-826.
31. Feng B., McQueney M.S., Mezzasalma T.M. and Slemmon J.R. (2001) An integrated ten-
pump eight-channel parallel LC/MS system for automated high throughput analysis of
proteins. Analytical Chemistry 73, 5691-5697.
7
J. Randall Slemmon
32. McNulty D.E. and Slemmon, J.R. (2004) Peptide Proteomics: Quantitative profiling of
endogenous low molecular weight polypeptides by multidimensional chromatographic
analysis. Molecular Biology 244, 411-423
33. United States Patent Application 200******** (March 27, 2003)
Methods of screening for agonists and agonists of the interaction between the AXOR8
(hGPR73) and AXOR52 receptors and ligands thereof: Inventors: Ames, Robert S. JR.;
(Haverford, PA) ; Sarau, Henry M.; (Harleysville, PA); Slemmon, J. ; (Glenview, IL) ;
McNulty, Dean E.; (Philadelphia, PA) ; Vawter, Lisa; (Coopersburg, PA) ; Foley, James
J.; (Radnor, PA).
34. Slemmon, J.R., Painter, C.L., Nadanaciva, S., Catana, F., Kaup, K., Scherrer, R.,
Casadas, V., Zhao, Y. (2005) Analysis of protein fragmentation inhibition by an MMP-
inhibitor in an in vivo model of heart failure using automated chromatography. J.
Chromatography B 819, 219-228.
35. Slemmon, J.R., Painter, C.L., Nadanaciva, S., Catana, F., Cook, A., Motter, R. and
Seubert, P. (2007) Distribution of Abeta peptide in whole blood. J. Chrom. B 846, 24-31.
38. Ditto, N., Kline, T., Alfinito, P., Slemmon, J. R., (2009) Enrichment and analysis of
Alzheimer’s Aβ1-42 peptide in human plasma and whole blood. J. Neurosci. Methods (in
press).
36. Slemmon J.R. et al. Isolation of Prokineticin 1(Bv8) from porcine brain and its activation of
two brain enriched orphan G-protein-coupled receptors. (on legal hold at GSK) J.
Neurochemistry.
37. Slemmon, J. Method of measuring amyloid-beta peptides using an ELISA. PCT Int. Appl.
(2006), 24 pp. CODEN: PIXXD2 WO 200-***-**** A2 20060518 CAN 144:484194
AN 2006:471912 CAPLUS
8
Contact this candidate